No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Eden Research announced on Thursday that it has signed an agreement with French animal health specialist Vto-pharma to supply thymol for use in bee care applications in the United States, marking a new commercial channel for one of its core bioactive ingredients.
The AIM-traded firm said thymol, a naturally derived compound found in plants such as thyme and oregano, was known for its antimicrobial and antifungal properties and is widely used across agriculture, pharmaceuticals, and consumer goods.
It is one of three active ingredients used in Eden's biopesticide formulations, and was already registered for use in both the EU and US.
Under the agreement, thymol would be incorporated into a varroa mite treatment developed by Vto-pharma for use in beehives.
"We are always looking for opportunities to leverage our existing registrations and technologies to diversify our product portfolio and revenue streams," said chief executive officer Sean Smith.
"This represents a meaningful contribution to that strategy, while also enhancing the return on investments made in active ingredient dossiers across the EU, the US, and other markets.
"We are pleased to be working with our new partner, Vto-pharma and supporting them in making their product a great success.
"We anticipate there will be additional opportunities in the future to further expand this relationship."
At 1125 BST, shares in Eden Research were up 3.21% at 2.89p.
Reporting by Josh White for Sharecast.com.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.